ReNeuron opens Boston office ahead of clinical trials

AIM-listed stem cell therapy specialist ReNeuron has opened an office in Boston that will initially house its US-based clinical, medical and scientific communications staff.

The company said the move reflects its focus on clinical development activities in the US across its therapeutic programmes. Next year, it plans to have three placebo-controlled Phase IIb clinical trials running with its CTX and hRPC cell therapy candidates, in stroke disability and retinal diseases. These will be carried out in clinical trial centres across the US.

ReNeuron said the establishment of a US office will allow it to more closely manage its relationships with the clinical research organisations and others involved in the conduct of these clinical trials and facilitate stronger ties with US-based key opinion leaders its areas of therapeutic focus.

Chief executive Olav Hellebø said: "We are delighted to have established operations in Boston, one of the US's most vibrant academic and commercial biotechnology hubs. The US is a major future market for our cell-based therapies and a presence on the ground represents a key element of ReNeuron's clinical and commercial development strategy as our therapeutic candidates move closer to market."

At 1020 GMT, the shares were down 1.8%to 1.82p.